Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia

Lung Cancer Clinical Trial

Official title:

Comparison of Emergence and Recovery Time, and Evaluation of Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia in Lung Surgery- A Pilot Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02324283
• Other study ID #: 12-97
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 2012
• Est. completion date: December 2024

Study information

• Verified date: April 2024
• Source: Juntendo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Which is more adequate general anesthetic agent, desflurane or propofol, for emergence and recovery time, and perioperative oxygenation in lung resection surgery?

Description:

The investigators plan to investigate the effects of desflurane on oxygenation (prevention of HPV) of OLV compare with propofol which is used in general anesthesia for lung resection.

Transesophageal echocardiography (TEE) wiill be used to measure pulmonary blood flow during surgery visible and successively. To confirm the effect of HPV by measuring the change in pulmonary blood flow. The correlation between the blood oxygen concentration and attenuation of blood flow will be investigated.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: December 2024
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients agree to participate in the study

• Patients undergoing lung cancer surgery requiring one-lung ventilation.

• American Society of Anesthesiologists Physical Status Class 1 or 2

Exclusion Criteria:

• Patients with any of the following will be excluded from lung cancer patients.

• New York Heart Association Classification more than 2

• Respiratory dysfunction Vital Capacity or percent predicted Forced expiratory volume in one second is less than 50 %

• Pulmonary hypertension with mean pulmonary arterial pressure more than 30 mmHg

• Coagulation dysfunction

• The administration of steroids and immunosuppressive agents within 3 months prior to surgery

• Infection with active inflammation

• Pneumonectomy patients

• Cases of epidural anesthesia is contraindicated

Related Conditions & MeSH terms

• Lung Cancer

Intervention

Drug:
• desflurane
Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia. Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.
• propofol
Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.

Locations

Country	Name	City	State
Japan	University of Juntendo	Bunkyo-ku	Tokyko

Sponsors (2)

Lead Sponsor	Collaborator
Juntendo University	Baxter Healthcare Corporation

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oxygenation	Arterial blood gases are monitored.Pulmonary blood flow is measured using transesophageal echocardiogram.	prior to surgery to one-hour after extubation
Secondary	Rapidity of Emergence From Anesthesia	Time to extubation and orientation, where the patient is.	one minute after cessation of anethetic agents to one hour after extubation
Secondary	Quality of Consiousness	quality of consciousness will be assessed using Aldrete score	after extubation
Secondary	Postoperative Nausea and Vomiting	degree of nausea and frequency of vomiting	on the postoperative day 1